Xention Pharma Limited

PlaqueTec, Ltd., a company focused on developing biomarker based therapies for coronary artery disease, has appointed Dr. Tim Brears CEO. Previously Brears was CEO of a company he founded in 2002, Xen

Verona Pharma plc, a drug development company focused on respiratory diseases, has appointed Ken Cunningham and Dr. Anders Ullman to its board of directors as non-executive directors – effective Sep.

IN VITRO DIAGNOSTICS Invitae Corp. Invitae brings in $40mm through Series E Molecular diagnostics firm Invitae Corp. raised $40mm through its Series E round. New and existing investors partici

The U.K. ion channel specialty company Xention Pharma Ltd. has spun out a new company, Ario Pharma Ltd ., to pursue the potential of TRPV1 antagonists in chronic cough. The U.S.-based venture cap